Skip to main content
Verona Pharma plc logo

Verona Pharma plc — Investor Relations & Filings

Ticker · VRNA ISIN · US9250501064 LEI · 213800EVI6O6J3TIAL06 US Manufacturing
Filings indexed 854 across all filing types
Latest filing 2025-11-17 Regulatory Filings
Country GB United Kingdom
Listing US VRNA

About Verona Pharma plc

https://www.veronapharma.com/

Verona Pharma plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for chronic respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company's lead product is ensifentrine (Ohtuvayre), a first-in-class, inhaled therapy designed to function as both a bronchodilator and an anti-inflammatory agent for the maintenance treatment of COPD. Following its acquisition, the company now operates as a subsidiary of Merck & Co., Inc.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-11-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-17 English
15-12G
Regulatory Filings
2025-10-17 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-10-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.